» Articles » PMID: 31116487

F-NaF PET/CT IMAGING IN FIBROUS DYSPLASIA OF BONE

Overview
Date 2019 May 23
PMID 31116487
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrous dysplasia (FD) is a mosaic skeletal disorder resulting in fractures, deformity, and functional impairment. Clinical evaluation has been limited by a lack of surrogate endpoints capable of quantitating disease activity. The purpose of this study was to investigate the utility of F-NaF PET/CT imaging in quantifying disease activity in patients with FD. Fifteen consecutively evaluated subjects underwent whole-body F-NaF PET/CT scans, and FD burden was assessed by quantifying FD-related F-NaF activity. F-NaF PET/CT parameters obtained included (i) SUV (standardized uptake value [SUV] of the FD lesion with the highest uptake); (ii) SUV (average SUV of all F-NaF-positive FD lesions); (iii) total volume of all F-NaF-positive FD lesions (TV); and (iv) total FD lesion activity determined as the product of TV multiplied by SUV (TA =  TV ×  SUV ) (TA). Skeletal outcomes, functional outcomes, and bone turnover markers were correlated with F-NaF PET/CT parameters. TV and TA of extracranial FD lesions correlated strongly with skeletal outcomes including fractures and surgeries (p values ≤ 0.003). Subjects with impaired ambulation and scoliosis had significantly higher TV and TA values (P < 0.05), obtained from extracranial and spinal lesions, respectively. Craniofacial surgeries correlated with TV and TA of skull FD lesions (P < 0.001). Bone turnover markers, including alkaline phosphatase, N-telopeptides, and osteocalcin, were strongly correlated with TV and TA (P < 0.05) extracted from FD lesions in the entire skeleton. No associations were identified with SUV or SUV . Bone pain and age did not correlate with F-NaF PET/CT parameters. FD burden evaluated by F-NaF-PET/CT facilitates accurate assessment of FD activity, and correlates quantitatively with clinically-relevant skeletal outcomes. © 2019 American Society for Bone and Mineral Research.

Citing Articles

18F-Sodium Fluoride PET/CT as a Tool to Assess Enthesopathies in X-Linked Hypophosphatemia.

Jimenez M, Sheppard A, Jaimovich R, Covarrubias N, Jordan D, Quintana J Calcif Tissue Int. 2025; 116(1):34.

PMID: 39864041 DOI: 10.1007/s00223-025-01343-3.


Jansen metaphyseal chondrodysplasia: analysis of craniofacial manifestations.

Obiezu F, Almpani K, Kim H, Zalewski C, Chu E, Jahanmir G JBMR Plus. 2025; 9(2):ziae156.

PMID: 39830149 PMC: 11736719. DOI: 10.1093/jbmrpl/ziae156.


Validation of quantitative [F]NaF PET uptake parameters in bone diseases: a systematic review.

de Ruiter R, Zwama J, Raijmakers P, Yaqub M, Burchell G, Boellaard R Ann Nucl Med. 2024; 39(2):98-149.

PMID: 39729191 PMC: 11799077. DOI: 10.1007/s12149-024-01991-9.


[F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders.

Zwama J, Rosenberg N, Verheij V, Raijmakers P, Yaqub M, Botman E Biomolecules. 2024; 14(10).

PMID: 39456213 PMC: 11505869. DOI: 10.3390/biom14101276.


Fibroblast Activation Protein Is Expressed by Altered Osteoprogenitors and Associated to Disease Burden in Fibrous Dysplasia.

Raborn L, Michel Z, Collins M, Boyce A, de Castro L Cells. 2024; 13(17.

PMID: 39273006 PMC: 11394668. DOI: 10.3390/cells13171434.


References
1.
Fendler W, Philippe Tiega D, Ilhan H, Paprottka P, Heinemann V, Jakobs T . Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013; 54(8):1202-8. DOI: 10.2967/jnumed.112.116426. View

2.
Czernin J, Satyamurthy N, Schiepers C . Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 2010; 51(12):1826-9. PMC: 3169430. DOI: 10.2967/jnumed.110.077933. View

3.
Majoor B, Leithner A, van de Sande M, Appelman-Dijkstra N, Hamdy N, Dijkstra P . Individualized approach to the surgical management of fibrous dysplasia of the proximal femur. Orphanet J Rare Dis. 2018; 13(1):72. PMC: 5932767. DOI: 10.1186/s13023-018-0805-7. View

4.
Hart E, Kelly M, Brillante B, Chen C, Ziran N, Lee J . Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res. 2007; 22(9):1468-74. DOI: 10.1359/jbmr.070511. View

5.
Lee J, FitzGibbon E, Chen Y, Kim H, Lustig L, Akintoye S . Clinical guidelines for the management of craniofacial fibrous dysplasia. Orphanet J Rare Dis. 2012; 7 Suppl 1:S2. PMC: 3359960. DOI: 10.1186/1750-1172-7-S1-S2. View